ONCOLOGIST
Scope & Guideline
Shaping the future of cancer care through open access.
Introduction
Aims and Scopes
- Clinical Trials and Treatment Innovations:
The journal focuses on the latest clinical trials and novel treatment strategies across various cancer types, emphasizing personalized medicine and immunotherapy. - Real-World Evidence and Outcomes:
It includes studies that analyze real-world data to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights into how therapies perform outside controlled clinical settings. - Molecular and Genomic Insights:
Research on the molecular and genetic characterization of tumors is a core theme, with an emphasis on identifying biomarkers that can predict treatment responses and outcomes. - Patient-Centered Care:
The journal highlights the importance of patient-reported outcomes, quality of life assessments, and the psychosocial aspects of cancer treatment, ensuring that patient perspectives are integrated into research. - Health Equity and Access to Care:
There is a growing emphasis on studies investigating disparities in cancer care, including access to treatments and outcomes among different demographic groups. - Innovative Methodologies:
The journal is open to novel research methodologies, including the use of artificial intelligence and machine learning in oncology, as well as advanced imaging and diagnostic techniques.
Trending and Emerging
- Immunotherapy and Combination Treatments:
There is a significant increase in publications centered around immunotherapy, particularly studies exploring combination therapies that enhance efficacy and manage resistance. - Liquid Biopsies and Non-Invasive Diagnostics:
Research focusing on liquid biopsies for early detection and monitoring of treatment responses is gaining traction, highlighting the shift towards less invasive diagnostic methods. - Artificial Intelligence in Oncology:
The application of AI and machine learning in predicting treatment outcomes and personalizing therapy is emerging as a vital area of research, reflecting technological advancements. - Patient-Centric Approaches:
An increased emphasis on patient-reported outcomes, survivorship issues, and quality of life assessments indicates a trend towards more holistic cancer care. - Health Disparities and Equity Research:
Research addressing health disparities and equity in cancer care is on the rise, emphasizing the need to address inequities in treatment access and outcomes across diverse populations. - Integrative Oncology:
The exploration of complementary therapies and integrative approaches alongside conventional treatments is becoming a more prominent theme, reflecting patient interest in holistic care.
Declining or Waning
- Traditional Chemotherapy Studies:
There appears to be a waning interest in studies focused solely on traditional chemotherapy regimens without the integration of novel agents or combination therapies, as the field moves towards more personalized and targeted approaches. - Single-Agent Studies:
Research solely examining the efficacy of single-agent therapies is becoming less prevalent, with a shift towards combination therapies that may enhance effectiveness and reduce resistance. - Basic Science without Clinical Application:
There is a noticeable reduction in papers that focus exclusively on basic science findings without a clear translational application to clinical settings, as the journal aims to bridge laboratory research and patient care. - Outdated Treatment Protocols:
Studies examining older treatment protocols, especially those that do not incorporate newer guidelines or advancements in cancer care, are becoming less common as the field rapidly evolves. - General Cancer Awareness Campaigns:
While important, general awareness programs are being overshadowed by more focused research on specific interventions, tailored treatments, and health disparities.
Similar Journals
JNCI-Journal of the National Cancer Institute
Driving excellence in cancer research since 1940.JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.
Oncology Reviews
Leading the Way in Open-Access Oncology ResearchOncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Driving clinical excellence through rigorous investigation.Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.
SEMINARS IN RADIATION ONCOLOGY
Advancing the Frontiers of Radiation OncologySEMINARS IN RADIATION ONCOLOGY is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, dedicated to advancing the field of radiation oncology through high-quality research and comprehensive reviews. With an impressive impact factor and a notable HIndex, this journal holds a prominent place within the academic community, particularly illustrated by its Q2 ranking in both Cancer Research and Oncology, and a Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. Since its inception in 1991, the journal has served as a vital resource for researchers, clinicians, and healthcare professionals, facilitating the exchange of innovative ideas and practices that shape the future of cancer treatment. While the journal is not open access, it offers essential insights into the latest advancements in the field, catering to a diverse audience eager to expand their knowledge and improve patient outcomes in the realm of radiation therapy.
CLINICAL ONCOLOGY
Unveiling New Frontiers in Cancer Research and DiagnosticsClinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.
International Journal of Clinical Oncology
Pioneering Discoveries in Clinical OncologyInternational Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.
ANNALS OF SURGICAL ONCOLOGY
Connecting research and practice for better patient care.The ANNALS OF SURGICAL ONCOLOGY, published by SPRINGER, stands as a leading journal dedicated to advancing the field of surgical oncology. With an ISSN of 1068-9265 and an E-ISSN of 1534-4681, this esteemed publication features high-quality research from 1994 to 2024, contributing significantly to the scientific dialogue surrounding surgical techniques, treatment innovations, and patient outcomes within the oncology community. The journal has earned a prestigious Q1 ranking in Surgery and a Q2 in Oncology for 2023, reflecting its pivotal role in influencing clinical practices and research in these fields. According to Scopus metrics, it ranks #51 out of 551 in Medicine Surgery and #133 out of 404 in Medicine Oncology, underscoring its academic rigor and impact. Despite being a subscription-based journal, the depth of knowledge disseminated through its pages is invaluable for researchers, professionals, and students aiming to stay at the forefront of surgical oncology advancements.
CURRENT PROBLEMS IN CANCER
Leading the Charge: Pioneering Solutions for Modern Cancer ProblemsCURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.
Oncology Research and Treatment
Uniting researchers to combat cancer effectively.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.
LANCET ONCOLOGY
Pioneering insights in the fight against cancer.The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.